Extramedullary plasmacytoma (EMP), multiple myeloma (MM), and solitary plasmacytoma of the bone (SPB) are each classified as distinct manifestations of a disease continuum with varying symptoms, treatment regimens, and prognostic implications. While the etiology for each of these neoplastic entities is due to a derangement of plasma cells, these B-cell neoplasms are indistinguishable histologically [1] [1]. EMP, a rare neoplasm, accounts for approximately 2–3% of all plasma cell tumors, SPB accounts for up to 4–6% of cases, and multiple myeloma for 91–94% [1] [2] [3].
http://ift.tt/2l28tTk
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου